OverviewSuggest Edit

Novoheart is a global stem cell biotechnology company that develops bioartificial human heart prototypes using a combination of stem cell and tissue engineering approaches. It engineers human heart constructs, and further develops them into transplantable grafts for cell-based regenerative heart therapies.
TypePublic
Founded2013
HQVancouver, CA
Websitenovoheart.com

Latest Updates

Share Price (Nov 2020)C$0.5
Cybersecurity ratingAMore

Key People/Management at Novoheart Holdings

James Topham

James Topham

Director, Audit Committee Chair
Camie Chan

Camie Chan

COO & Interim CFO
Katherine Ngan Ng Yu Ying

Katherine Ngan Ng Yu Ying

Director, Deputy Chair of the Board
Ricky Chiu

Ricky Chiu

Director
Roger Ngan

Roger Ngan

Director, GNC Committee
Kevin Costa

Kevin Costa

CSO & Scientific Co-Founder
Show more

Novoheart Holdings Office Locations

Novoheart Holdings has offices in Vancouver and Irvine
Vancouver, CA (HQ)
1430 W Pender St
Vancouver, CA
2600-595 Burrard St
Irvine, CA, US
5270 California Ave #300
Show all (5)

Novoheart Holdings Financials and Metrics

Novoheart Holdings Revenue

Market capitalization (19-Nov-2020)

98.1m

Closing stock price (19-Nov-2020)

0.5
Novoheart Holdings's current market capitalization is C$98.1 m.
Show all financial metrics

Novoheart Holdings Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Novoheart Holdings Online and Social Media Presence

Embed Graph

Novoheart Holdings News and Updates

Novoheart Holdings Inc. has Closed its Going-Private Transaction

VANCOUVER, British Columbia, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH) is pleased to announce that the previously announced acquisition by Novomed Limited (the “Purchaser”), a company beneficially owned by entities controlled by Prof. Rona…

Novoheart Holdings Inc. Receives Securityholder Approval of Going-Private Transaction

VANCOUVER, British Columbia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH) is pleased to announce that the previously announced acquisition by Novomed Limited (the “Purchaser”), a company beneficially owned by entities controlled by Prof. Rona…

Novoheart Holdings Inc. Enters into Definitive Agreements for Going-Private Transaction

VANCOUVER, British Columbia, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH) announces that it has entered into a definitive arrangement agreement (the “Arrangement Agreement”) with Novomed Limited (the “Purchaser”), a company controlled by Pro…

Novoheart Holdings Inc. Reports Second Quarter 2020 Financial Results

VANCOUVER, British Columbia, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and six months ended June 30, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with Intern…

Novoheart Holdings Frequently Asked Questions

  • When was Novoheart Holdings founded?

    Novoheart Holdings was founded in 2013.

  • Who are Novoheart Holdings key executives?

    Novoheart Holdings's key executives are James Topham, Camie Chan and Katherine Ngan Ng Yu Ying.

  • Who are Novoheart Holdings competitors?

    Competitors of Novoheart Holdings include IVTech, Qkine and Afyren.

  • Where is Novoheart Holdings headquarters?

    Novoheart Holdings headquarters is located at 1430 W Pender St, Vancouver.

  • Where are Novoheart Holdings offices?

    Novoheart Holdings has offices in Vancouver and Irvine.

  • How many offices does Novoheart Holdings have?

    Novoheart Holdings has 5 offices.